Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Mayo Clinic

Founders Augustus Stinchfield Charles Horace Mayo Christopher Graham Donald Balfou Henry Stanley Plummer Melvin Millet William James Mayo


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 66
Average round size
The average size of a deal this fund participated in
Portfolio companies 51
Rounds per year 0.64
Lead investments 3
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 6
Key employees 9

Areas of investment

  • Health Care
  • Biotechnology
  • Medical
  • Health Diagnostics
  • Software

Mayo Clinic appeared to be the Corporate Investor, which was created in 1919. The main department of described Corporate Investor is located in the Rochester. The company was established in North America in United States.

The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the Mayo Clinic, startups are often financed by Canaan Partners, Social Capital, Three Arch Partners. The meaningful sponsors for the fund in investment in the same round are Three Arch Partners, MPM Capital, Bay City Capital. In the next rounds fund is usually obtained by Venrock, Three Arch Partners, Sands Capital Ventures.

For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. Among the most popular fund investment industries, there are Biopharma, Artificial Intelligence. Among the most popular portfolio startups of the fund, we may highlight Helix, DayTwo, AliveCor. The fund has no specific favorite in a number of founders of portfolio startups. If startup sums 4 of the founder, the chance for it to be financed is low.

The current fund was established by Augustus Stinchfield, Charles Horace Mayo, Christopher Graham, Donald Balfou, Henry Stanley Plummer, Melvin Millet, William James Mayo. We also calculated 8 valuable employees in our database.

The higher amount of exits for fund were in 2018. The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in 2-6 investment rounds annually. The real fund results show that this Corporate Investor is 8 percentage points less often commits exit comparing to other companies. The important activity for fund was in 2014. Despite it in 2019 the fund had an activity. The average startup value when the investment from Mayo Clinic is 50-100 millions dollars. This Mayo Clinic works on 17 percentage points less the average amount of lead investments comparing to the other organizations.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Mayo Clinic:
Typical Co-investors
Mayo Clinic is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Mayo Clinic:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
AdUX France, Ile-de-France, Paris
Anomaly Ventures -
Aurion Capital Canada, Ontario, Toronto
BM&FBOVESPA S.A. Brazil, São Paulo, Sao Paulo
Chromo Invest Brazil, Porto Alegre, Rio Grande do Sul
Clermont Group Central Region, Singapore, Singapore
Dynafund Ventures California, Torrance, United States
Encourage Technologies Hokkaido Prefecture, Japan, Sapporo
Frontive Holding Limited -
IPB Capital Central, Central Region, Singapore
Manuardeo -
Mysteel Global Baoshan, China, Shanghai
North Atlantic Capital Maine, Portland, United States
Nounos Creamery New York, New York, United States
RDseed Israel, Tel Aviv, Tel Aviv District
Siemens Mustang Ventures California, Santa Clara, United States
Socadif -
Tata Consultancy Services India, Maharashtra, Mumbai
Zhixin Zede Touzi -

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Nucleus RadioPharma

Health Care
$6M12 Oct 2022 Rochester, New York, United States


29 Aug 2022 Kanata, Ontario, Canada

Senda Biosciences

Life Science
$123M16 Aug 2022 Cambridge, Massachusetts, United States

Diagnostic Robotics

Artificial Intelligence
Health Care
Machine Learning
$45M25 Jul 2022 Tel Aviv-Yafo, Tel Aviv District, Israel

Lisa Health

Health Care
Medical Device
$2M22 Jul 2022 Oakland, California, United States

Aesop Technology

Artificial Intelligence
Digital Media
Health Care
$200K18 Jul 2022 Cambridge, Massachusetts, United States


Artificial Intelligence
Cloud Computing
Cyber Security
Internet of Things
Machine Learning
Network Security
$40M01 Jun 2022 San Jose, California, United States

Karkinos Healthcare

Health Care
23 May 2022 Mumbai, Maharashtra, India


$29M17 May 2022 Rochester, Minnesota, United States
SimBioSys Raises $15 Million Series A to Develop the Future of Precision Cancer Care

– SimBioSys announced it raised $15m in Series A funding to accelerate the development and commercialization of its TumorScope software platform.
– The company’s novel, simulation-based, precision medicine platform enables individualized treatment planning for cancer patients.
– This Series A was co-led by Genoa Ventures and Northpond Ventures, with participation from AV8 Ventures, Heritage Medical Group, and Mayo Clinic.
– Existing investors and founders also participated in this financing round, bringing the company’s total capital raised to $21m.
– In the first half of 2021, SimBioSys tripled its headcount, bringing in expert clinicians, scientists, and executives from the life sciences industry.

TripleBlind secures $24M for a new approach to enterprise-level, privacy-preserving data sharing

– TripleBlind, a startup that has devised a way to encrypt data so that it can be shared without ever being decrypted or even leaving the data owner’s firewall, and keeping the whole process compliant with data protection regulations, raised $24m in Series A funding.
– The round was co-led by General Catalyst and the Mayo Clinic, with AVG Basecamp Fund, Accenture Ventures, Clocktower Technology Ventures, Dolby Family Ventures, Flyover Capital, KCRise Fund, NextGen Venture Partners and Wavemaker Three-Sixty Health also participating.
– The company estimates there are some 43 zetabytes of data stored by enterprises today globally that is not being used as it could be because of the limitations imposed both by these and other data protection rules, as well as general hesitancy over sharing IP and other issues around sharing data.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Mayo Clinic?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: